Skip to main content
Premium Trial:

Request an Annual Quote

Michael Dent, Dennis Robbins, Geoffrey Ginsburg, Nicola Campbell, Jai Nagarkatti, David Harvey

Premium

NeoGenomics Chairman Michael Dent has been appointed managing director at the company. Dent will now lead the company’s efforts in developing new clinical lab services and collaborative research projects.


GenoMed has named Dennis Robbins chairman of the company’s newly created business advisory board.

Robbins has served as a visiting scholar and research fellow in medical ethics in the Harvard School of Public Health, and has been an advisor to the President’s Commission on Ethics in Biomedicine and Biomedical Research.


Duke University’s Institute for Genome Sciences and Policy has hired Geoffrey Ginsburg as director of genomic medicine. He will assume his position Sept. 1. He will direct the ways in which the IGSP can use genetic data to “tailor preventive health-care plans for individual patients,” which Duke said is part of its “larger effort to promote a new era of personalized medicine.”

Ginsburg comes to the IGSP from Millennium Pharmaceuticals, where he was vice president of molecular and personalized medicine. He received his MD and PhD degrees from Boston University.

Ginsburg will join the faculty in the department of medicine at Duke University Medical Center.


Sofinnova Ventures, a San Francsico-based venture firm investing in early-stage life science companies, said that Nicola Campbell has joined as a life science partner.

Campbell was previously a principal with BA Venture Partners, where she focused on mid-stage investment opportunities in drug discovery and product-based companies. Prior to this, she was at Burrill & Co., a life science merchant banking firm focusing on biotechnology venture capital. She has also been employed by Genentech in business development and scientific roles. She received a PhD in molecular and cellular immunology from Mount Sinai Medical Center.


Sigma-Aldrich has promoted Jai Nagarkatti, president of the company’s scientific research business unit, to the president and chief operating officer. He replaces David Harvey, who will continue as chairman of the board and CEO of the company. Three business units — scientific research, biotechnology, and fine chemicals — will now report to Nagarkatti.

Nagarkatti’s 28-year career at Sigma-Aldrich has spanned R&D, manufacturing, operations, and sales and marketing, the company said. Prior to his role as president of the scientific research business unit, he was president of the fine chemicals business. Nagarkatti holds an MS in chemistry from Osmania University in India, and a PhD in organic chemistry from Texas A&M University-Commerce.

 

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.